List of Excipients in Branded Drug DOXAPRAM HYDROCHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	DOXAPRAM HYDROCHLORIDE	doxapram hydrochloride	51662-1404	BENZYL ALCOHOL
HF Acquisition Co LLC DBA HealthFirst	DOXAPRAM HYDROCHLORIDE	doxapram hydrochloride	51662-1404	WATER

Doxapram Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

Doxapram hydrochloride is an old small-molecule respiratory stimulant with limited modern human use and a more durable veterinary opportunity. The strongest commercial strategy is a sterile, preservative-free injectable platform built around formulation simplicity, low extractables and leachables, rapid administration, and supply reliability. Excipient differentiation is unlikely to create broad composition-of-matter protection, but it can support regulatory differentiation, hospital procurement, and selected formulation patents.

What is the current commercial position of doxapram hydrochloride?

Doxapram hydrochloride is a centrally acting respiratory stimulant administered primarily by injection. The historical U.S. product, DOPRAM Injection, was indicated for postoperative respiratory depression and acute respiratory failure associated with chronic obstructive pulmonary disease when reversible airway obstruction was suspected or present.[1]

Its human commercial position is constrained by:

• Narrow clinical use compared with mechanical ventilation, noninvasive ventilation, naloxone, caffeine citrate, and other respiratory-support interventions.
• Cardiovascular and central nervous system adverse effects.
• A limited role in current critical-care protocols.
• The age of the active ingredient and the absence of meaningful new chemical-entity exclusivity.
• Competition from hospital compounding, legacy generic injectables, and veterinary products.

Doxapram remains commercially relevant where clinicians require a rapid-acting respiratory stimulant and where veterinary anesthetic recovery protocols use the product. Veterinary formulations may offer a more stable market than human hospital use, particularly in injectable products for dogs, cats, horses, and other species.

What excipients are used in doxapram hydrochloride injection?

The reference injectable formulation is an aqueous sterile solution of doxapram hydrochloride. Public product labeling identifies water for injection and formulation excipients used to control tonicity and pH.[1] The precise commercial formulation should be confirmed against the applicable current label, regulatory filing, and manufacturing specification.

A practical excipient platform would typically evaluate the following functions:

Formulation function	Candidate excipient approach	Commercial rationale
Vehicle	Water for injection	Standard parenteral vehicle with low regulatory complexity
pH control	Acetate or citrate buffer; hydrochloric acid or sodium hydroxide for adjustment	Supports chemical stability and injection tolerability
Tonicity	Sodium chloride or sodium-containing buffer	Reduces hemolysis and injection discomfort
Antimicrobial preservation	Avoid where feasible; otherwise assess an approved preservative	Preservative-free positioning is stronger for critical-care use
Oxidation control	Minimize oxygen exposure; evaluate an antioxidant only if required	Limits excipient burden and compatibility risk
Container protection	Amber or light-resistant packaging if photostability requires it	Supports shelf-life and product quality
Syringe lubrication	Silicone oil or alternative low-lubricant system	Important for prefilled syringes and extractables control

The preferred starting formulation is a low-excipient, preservative-free solution in a single-dose vial or ready-to-use syringe. Adding a complex excipient system would increase extractables, leachables, container-closure, sterilization, and regulatory risks without necessarily improving clinical value.

Which excipient attributes matter most for doxapram hydrochloride?

pH and chemical stability

Doxapram hydrochloride is a salt-form active pharmaceutical ingredient intended for aqueous injection. The development program should establish:

• pH-solubility behavior.
• Degradation under heat, light, oxygen, and agitation.
• Compatibility with acetate, citrate, phosphate, and unbuffered systems.
• Risk of precipitation after dilution.
• Stability in common infusion fluids.
• Compatibility with administration sets, pumps, and syringes.

A narrow buffer system may improve pH control but can reduce flexibility when the product is diluted into clinical fluids. An unbuffered or lightly buffered formulation may simplify dilution compatibility but can expose the product to greater pH drift.

Osmolality and injection tolerability

The formulation should target acceptable osmolality for intravenous administration while avoiding unnecessary sodium loading. If the commercial label permits intramuscular or subcutaneous administration, the tolerability profile for those routes must be assessed separately.

Tonicity adjustment with sodium chloride is familiar to regulators and hospital pharmacies. However, a sodium-containing acetate system may provide both buffering and tonicity, reducing the total excipient count.

Preservative strategy

A preservative-free, single-dose presentation is commercially preferable for acute-care injection. It reduces concerns regarding repeated puncture, benzyl alcohol exposure, neonatal use, and preservative compatibility with vulnerable patients.

A multidose vial could reduce packaging cost, but its commercial value is less clear because doxapram is used in intermittent acute-care settings. A multidose configuration would require antimicrobial effectiveness data and a clear use pattern that justifies the added formulation and labeling burden.

Container-closure compatibility

The main commercial risk may come from the package rather than the excipient list. Development should compare:

• Type I glass vials.
• Polymer vials.
• Plastic ampoules.
• Prefilled glass syringes.
• Ready-to-use polymer syringes.

The program should test adsorption, tungsten-related particles, silicone oil, stopper extractables, and leachables. A prefilled syringe could create a meaningful hospital-use advantage, but it requires more extensive device, stability, and human-factors work than a conventional vial.

What formulations are protected by doxapram patents?

Doxapram hydrochloride is an old active ingredient. Core compound and early-use patent protection would generally have expired long before the current product cycle. Commercial protection is therefore more likely to involve:

• A specific concentration.
• A stable aqueous formulation.
• A preservative-free presentation.
• A prefilled syringe or cartridge.
• A particular buffer system.
• A lyophilized product requiring reconstitution.
• A manufacturing process that reduces impurities.
• A container-closure system.
• A veterinary dosage form.
• A method of use in a defined patient population.

A formulation patent would need a defensible technical difference. Merely replacing sodium chloride with another tonicity agent or changing the pH within a conventional range may face obviousness challenges unless the applicant demonstrates an unexpected stability, compatibility, safety, or administration benefit.

The strongest potential claims would link the excipient system to measurable performance, such as:

1. Extended room-temperature stability.
2. Reduced degradation impurities.
3. Improved compatibility with infusion fluids.
4. Reduced particulate formation.
5. Improved syringe dose accuracy.
6. Lower injection-site irritation.
7. Preservative-free multidose stability, if technically achievable.

When does doxapram hydrochloride lose exclusivity?

Doxapram hydrochloride has no meaningful remaining new-molecule exclusivity in the United States. The active ingredient was developed and marketed decades ago, and any original composition-of-matter term has expired.

Current exclusivity analysis must distinguish four categories:

Exclusivity category	Relevance to doxapram hydrochloride
New chemical entity exclusivity	Expired
Core compound patents	Expected to be expired
Product-specific formulation patents	Possible, but must be verified in current patent records
Regulatory exclusivity for a new formulation	Possible only after a qualifying approval

A new formulation could receive limited regulatory protection if it qualifies as a new drug product or a new clinical indication, but the opportunity would depend on the clinical and regulatory pathway. A conventional injectable reformulation would not automatically receive meaningful market exclusivity.

What is the Orange Book status of doxapram hydrochloride?

The Orange Book is relevant only to approved U.S. drug products and patents properly listed against those products.[2] For an ANDA applicant, the commercial question is whether a currently approved reference listed drug exists and whether active patents or exclusivity periods are listed.

For doxapram hydrochloride, the likely strategic position is:

• The core active ingredient is available for generic development.
• Any current patent barrier would be product-specific rather than molecule-wide.
• A Paragraph IV certification would matter only if an active, listed patent covers the reference product.
• An applicant should not assume that an old marketed product has an active Orange Book patent estate.
• The current Orange Book and Drugs@FDA records should control any filing decision.[2,3]

An ANDA sponsor would normally evaluate Paragraph I, II, III, or IV certification based on the live patent record. If no unexpired listed patent remains, the filing could avoid a Paragraph IV litigation pathway.

Which companies are challenging doxapram hydrochloride exclusivity?

There is no well-established modern innovator-versus-generic litigation profile comparable with high-value branded products. The commercial field is more likely to contain generic manufacturers, specialty injectable companies, and veterinary pharmaceutical companies competing through supply, price, presentation, and regulatory execution.

The main competitive groups are:

• Legacy generic injectable manufacturers.
• Contract manufacturers with sterile fill-finish capacity.
• Veterinary pharmaceutical companies.
• Hospital suppliers seeking a shortage-resistant product.
• Specialty pharmaceutical companies repackaging or relaunching discontinued products.

A new entrant would compete less against patent litigation than against manufacturing economics, regulatory maintenance, demand variability, and hospital formulary penetration.

What generic entry risks exist for doxapram hydrochloride?

Generic entry risk is high because the active ingredient is old and the likely formulation is relatively simple. The principal barriers are technical rather than patent-based.

Regulatory risks

An ANDA applicant must establish pharmaceutical equivalence and bioequivalence or another acceptable basis for approval. Injectable solutions can be simpler than oral products when the active and inactive ingredients are qualitatively and quantitatively comparable, but differences in excipients, concentration, pH, preservative content, and packaging can still create review issues.[4]

Manufacturing risks

The critical manufacturing risks include:

• Sterile filtration and aseptic processing.
• Control of bioburden and endotoxins.
• Particulate contamination.
• pH drift during storage.
• Container-closure integrity.
• Supply of high-quality doxapram hydrochloride API.
• Batch-scale reproducibility.
• Stability after dilution.

Commercial risks

Demand may be too low to support multiple suppliers. A manufacturer that cannot maintain consistent availability may lose hospital contracts even with an approved product. Small-volume sterile products are vulnerable to:

• Low production runs.
• Rising fill-finish costs.
• Component shortages.
• Quality-system remediation.
• Expired or discontinued reference products.
• Weak purchasing volumes.

What commercial opportunities exist for doxapram excipient innovation?

Preservative-free ready-to-use injection

A single-dose, preservative-free syringe could reduce preparation time and medication-error risk. The product would be positioned for emergency departments, operating rooms, intensive-care units, and veterinary anesthesia settings.

Stable diluted formulation

A formulation with demonstrated compatibility in common infusion fluids could offer operational value. The supporting package would need dilution stability data, administration-set compatibility, and clear labeling.

Veterinary-specific products

Veterinary products may support differentiated strengths, package sizes, and dosing accessories. Commercial opportunities include:

• Small-volume injectable vials.
• Multi-animal clinic packs.
• Ready-to-use syringes.
• Species-specific labeling.
• Anesthesia-recovery kits.
• Products designed for emergency veterinary hospitals.

Veterinary development must address species-specific safety, dosing, withdrawal requirements where relevant, and regulatory requirements under the applicable animal-drug pathway.

Low-temperature or simplified supply-chain products

A formulation with documented room-temperature stability could reduce cold-chain dependence. This would be valuable for veterinary practices, emergency stockpiles, and lower-volume hospitals. The claim must be supported by real-time and accelerated stability studies.

Combination rescue kits

A commercial kit containing doxapram hydrochloride with administration accessories, labeling, and emergency-use instructions could improve workflow. The kit would not necessarily create pharmaceutical exclusivity, but it could increase purchasing convenience and customer retention.

How strong is the patent estate for doxapram hydrochloride?

The estate is likely weak at the active-ingredient level and potentially moderate at the formulation or device level.

Protection layer	Expected strength
Active ingredient	Very weak; historic protection expired
Conventional aqueous injection	Weak unless supported by unexpected results
Preservative-free formulation	Moderate if stability or safety advantages are demonstrated
Prefilled syringe	Moderate; depends on device and formulation claims
Veterinary indication	Potentially moderate, but method-of-use scope may be narrow
Manufacturing process	Moderate if impurity control is difficult to replicate
Packaging and kit configuration	Limited pharmaceutical exclusivity; useful commercially

A formulation patent should be drafted around measurable technical results rather than broad excipient lists. The application should include comparative examples across pH, buffer concentration, oxygen exposure, container materials, and storage conditions.

What patent litigation affects doxapram hydrochloride?

No major current patent litigation appears to define the commercial market in the way seen with high-revenue branded drugs. The principal legal risks are more likely to arise from:

• Patent claims covering a newly approved formulation.
• ANDA certification disputes.
• Trade-secret claims involving sterile manufacturing.
• Contract disputes over supply or technology transfer.
• Trademark and product-labeling disputes.
• Regulatory exclusivity attached to a newly approved indication.

A company launching a conventional generic injection should prioritize freedom-to-operate review of recent formulation, syringe, packaging, and veterinary-use filings rather than focusing only on historical doxapram compound patents.

How does doxapram compare with competing respiratory stimulants?

Product	Main use context	Formulation opportunity	Competitive position
Doxapram hydrochloride	Acute respiratory stimulation; veterinary anesthesia recovery	Injectable vial, syringe, veterinary formats	Narrow human market; stronger niche potential
Caffeine citrate	Apnea of prematurity	Sterile oral and injectable dosage forms	Strong neonatal position; different clinical segment
Naloxone hydrochloride	Opioid-induced respiratory depression	Vial, ampoule, autoinjector, nasal spray	Much larger emergency market
Mechanical or noninvasive ventilation	Respiratory support	Device-based	Dominant alternative in severe respiratory failure
Respiratory-support combinations	Critical-care use	Hospital-specific	Often displace pharmacologic stimulants

Doxapram cannot compete with naloxone in opioid reversal or with caffeine citrate in neonatal apnea. Its commercially defensible niches are rapid injectable availability, veterinary use, and selected rescue applications.

What is the FDA regulatory pathway for a new doxapram product?

A conventional generic injectable would generally pursue an ANDA if an appropriate reference listed drug and regulatory pathway are available.[4] A materially different formulation, new indication, new delivery system, or product without a suitable reference could require an NDA or another FDA pathway.

The development sequence should include:

1. Reference-product characterization.
2. API qualification and impurity profiling.
3. Excipient compatibility screening.
4. Forced-degradation studies.
5. Sterile process development.
6. Container-closure selection.
7. Comparative analytical testing.
8. Stability studies.
9. Extractables and leachables evaluation.
10. Regulatory pathway confirmation.

The FDA’s Inactive Ingredient Database can help assess whether proposed excipients and route-specific levels have precedent, although precedent does not eliminate the need for product-specific safety and quality data.[5]

Key Takeaways

• Doxapram hydrochloride has limited human commercial demand but credible veterinary and specialty-injectable opportunities.
• The preferred formulation is a simple, sterile, preservative-free aqueous injection.
• Sodium-containing buffering and tonicity systems should be evaluated before adding novel excipients.
• A ready-to-use syringe could create stronger commercial differentiation than a conventional vial.
• Core compound patents and new-molecule exclusivity are no longer meaningful barriers.
• Formulation, packaging, manufacturing, and device patents offer the most plausible protection.
• Generic entry risk is high, with sterile manufacturing and supply reliability as the main barriers.
• Veterinary products may provide a more attractive commercial platform than a broad human hospital launch.
• A formulation patent should rely on demonstrated stability, compatibility, impurity, or administration benefits.
• Orange Book and Drugs@FDA records must be checked before making any ANDA or Paragraph IV decision.

FAQs

Can doxapram hydrochloride be formulated as a preservative-free injection?

Yes. A single-dose preservative-free aqueous injection is a commercially practical target and may be preferable for acute-care and veterinary use. The product must meet sterility, particulate, stability, and container-closure requirements.

Is doxapram hydrochloride suitable for a prefilled syringe?

Yes, subject to compatibility with the syringe barrel, plunger, lubricant, stopper, and sterilization process. A prefilled syringe could reduce preparation time but would require device and extractables-and-leachables development.

Can a new buffer system create patent protection for doxapram?

Potentially, but a routine buffer substitution is unlikely to provide strong protection by itself. Patent value improves when the buffer produces unexpected stability, reduced impurities, better dilution compatibility, or improved injection tolerability.

Is there a biosimilar pathway for doxapram hydrochloride?

No. Doxapram hydrochloride is a chemically synthesized small molecule, not a biologic. The relevant U.S. pathway is generally generic-drug regulation, such as an ANDA, when an appropriate reference product exists.

Which market is more attractive, human or veterinary doxapram?

Veterinary doxapram may offer the stronger niche opportunity because human use is limited by competing respiratory-support therapies and restricted clinical demand. The commercial outcome depends on regulatory status, existing suppliers, veterinary adoption, and achievable sterile manufacturing cost.

References

1. U.S. Food and Drug Administration. (n.d.). DOPRAM (doxapram hydrochloride) injection prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.

4. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format. FDA.

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.